Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Repare Therapeutics Inc's Business Segments
Repare Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Customer One
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Customer One0%
- Bristol-Myers Squibb Company0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Customer One | $ 0 | - |
| Bristol-Myers Squibb Company | $ 0 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Customer One0%
- Bristol-Myers Squibb Company0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Customer One | $ 0 | - |
| Bristol-Myers Squibb Company | $ 0 | - |
Description of Repare Therapeutics Inc
Repare Therapeutics Inc. is a biotech company that focuses on the development of innovative precision cancer therapies using its proprietary SNIPRx platform. The company's platform uses synthetic lethality, a mechanism where targeting two genes would result in cell death, to identify novel and selective targets for the treatment of cancer.
Repare's technology works by screening synthetic lethality pairs in a large library of cancer cells to identify targets that are crucial for cancer cell survival. The company then develops small molecule drug candidates that selectively target these vulnerabilities without harming healthy cells.
Repare's pipeline includes four preclinical programs and one clinical program, RP-3500, which is a potential first-in-class oral small molecule targeted therapy that inhibits DNA-PK, a kinase that plays a critical role in DNA damage response and repair pathways that are essential for cancer cell survival. RP-3500 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
Additionally, Repare has collaborations with industry leaders like Bristol Myers Squibb and Vertex Pharmaceuticals to develop innovative cancer therapies using its SNIPRx platform.
Apart from its novel technology, Repare also has a robust intellectual property portfolio, comprising more than 50 patent applications with worldwide coverage.
The company's leadership team comprises world-renowned scientists with extensive experience in genomic medicine, synthetic lethality, and drug discovery, including CEO Lloyd M. Segal, Chief Medical Officer Dr. Steve Murray, and Chief Scientific Officer Dr. Michael Zinda.
Based in Montreal, Canada, Repare is backed by leading investors like Versant Ventures, MPM Capital, and Orbimed Advisors, among others. The company's vision is to become a leader in precision oncology by developing groundbreaking cancer treatments that help patients live longer and healthier lives.
Repare's technology works by screening synthetic lethality pairs in a large library of cancer cells to identify targets that are crucial for cancer cell survival. The company then develops small molecule drug candidates that selectively target these vulnerabilities without harming healthy cells.
Repare's pipeline includes four preclinical programs and one clinical program, RP-3500, which is a potential first-in-class oral small molecule targeted therapy that inhibits DNA-PK, a kinase that plays a critical role in DNA damage response and repair pathways that are essential for cancer cell survival. RP-3500 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
Additionally, Repare has collaborations with industry leaders like Bristol Myers Squibb and Vertex Pharmaceuticals to develop innovative cancer therapies using its SNIPRx platform.
Apart from its novel technology, Repare also has a robust intellectual property portfolio, comprising more than 50 patent applications with worldwide coverage.
The company's leadership team comprises world-renowned scientists with extensive experience in genomic medicine, synthetic lethality, and drug discovery, including CEO Lloyd M. Segal, Chief Medical Officer Dr. Steve Murray, and Chief Scientific Officer Dr. Michael Zinda.
Based in Montreal, Canada, Repare is backed by leading investors like Versant Ventures, MPM Capital, and Orbimed Advisors, among others. The company's vision is to become a leader in precision oncology by developing groundbreaking cancer treatments that help patients live longer and healthier lives.
Repare Therapeutics Inc. is a cutting-edge pharmaceutical company dedicated to transforming cancer treatment through innovative approaches based on the principles of synthetic lethality. By leveraging genetic vulnerabilities inherent in cancer cells, Repare aims to develop more effective and personalized therapies that selectively target these weaknesses while sparing healthy cells.
Segments
Repare Therapeutics operates primarily within the biotechnology sector, concentrating on personalized oncology therapies. The company is organized into two main segments:
1. Drug Discovery and Development:
- Synthetic Lethality Focus: This segment centers on the discovery and development of therapies that utilize synthetic lethality to precisely target cancer cells. The company employs its proprietary technology platform, known as SNIPRx, to systematically identify and validate novel synthetic lethal targets. This involves mapping genetic interactions within cancer cells to inform the development of new precision medicines.
- Pipeline Robustness: Repares pipeline features multiple product candidates at various stages of development, reflecting a commitment to addressing diverse oncological needs through a novel therapeutic approach.
2. Companion Diagnostics:
- Predictive Tools for Treatment: In conjunction with its drug development efforts, Repare Therapeutics is focused on creating companion diagnostics that enable the identification of specific genetic mutations and biomarkers. These diagnostics are crucial for predicting which patients will respond favorably to Repares synthetic lethality-based therapies.
- Enhancing Personalized Medicine: Through the alignment of companion diagnostics with therapeutic candidates, Repare reinforces its commitment to personalized medicine, ensuring that treatment is tailored to the individual genetic profile of patients.
Products
Repare Therapeutics has several key product candidates in its development pipeline aimed at addressing various cancer types:
1. RP-3500:
- Lead Product Candidate: Representing Repare’s flagship program, RP-3500 is under development to exploit a synthetic lethal interaction between the MGMT gene and ATR (Ataxia Telangiectasia and Rad3-related protein).
- Current Development Stage: Primarily in Phase 1 clinical trials, RP-3500 is being evaluated for efficacy in treating solid tumors, including cancers of the ovarian, lung, and colon, which are characterized by specific genetic alterations that may make them susceptible to this treatment.
2. RP-6306:
- Targeting POLQ and PARP Interaction: This product candidate aims at a synthetic lethal relationship between the POLQ (DNA polymerase theta) and PARP (Poly (ADP-ribose) polymerase). This interaction is particularly relevant in various malignancies where mutations confer a vulnerability to therapeutic intervention.
- Development Status: Currently positioned in preclinical development, Repare has plans to transition RP-6306 into clinical trials shortly, indicating a strong pipeline progression.
3. Companion Diagnostics:
- Early Stage Development: The company is also investing efforts in the development of companion diagnostics aimed at recognizing genetic markers that are indicative of tumor responses to their drug candidates. These tools are intended to be integrated with treatment regimens to enhance therapeutic success rates.
Services
In addition to its product offerings, Repare Therapeutics provides a suite of services that support drug discovery and development processes:
1. SNIPRx Platform:
- Innovative Drug Discovery Approach: The SNIPRx platform employs CRISPR technology to identify and validate synthetic lethal targets efficiently. This innovative approach positions Repare at the forefront of identifying novel therapeutic targets that can lead to more effective treatment options.
2. Preclinical and Clinical Development Services:
- Comprehensive Support: Repare possesses significant expertise in both preclinical and clinical development. The company is well-equipped to collaborate with partners by providing services spanning the entirety of drug development phases, from initial target identification through rigorous clinical trial processes.
3. Biomarker Discovery:
- Customized Biomarker Solutions: Repare is involved in biomarker development aimed at profiling caseloads to improve therapeutic outcomes. The company offers services that include the identification and validation of biomarkers, as well as the creation of tailored biomarker panels that align with specific cancer types, facilitating a more precise approach to oncology treatment.
Conclusion
Repare Therapeutics Inc. stands out in the biotechnology landscape with its focus on synthetic lethality, advancing both drug candidates and companion diagnostics to significantly improve cancer treatment outcomes. By harnessing innovative technological platforms and personalized approaches, Repare is positioned to make a substantial impact on the future of oncology therapies.
Segments
Repare Therapeutics operates primarily within the biotechnology sector, concentrating on personalized oncology therapies. The company is organized into two main segments:
1. Drug Discovery and Development:
- Synthetic Lethality Focus: This segment centers on the discovery and development of therapies that utilize synthetic lethality to precisely target cancer cells. The company employs its proprietary technology platform, known as SNIPRx, to systematically identify and validate novel synthetic lethal targets. This involves mapping genetic interactions within cancer cells to inform the development of new precision medicines.
- Pipeline Robustness: Repares pipeline features multiple product candidates at various stages of development, reflecting a commitment to addressing diverse oncological needs through a novel therapeutic approach.
2. Companion Diagnostics:
- Predictive Tools for Treatment: In conjunction with its drug development efforts, Repare Therapeutics is focused on creating companion diagnostics that enable the identification of specific genetic mutations and biomarkers. These diagnostics are crucial for predicting which patients will respond favorably to Repares synthetic lethality-based therapies.
- Enhancing Personalized Medicine: Through the alignment of companion diagnostics with therapeutic candidates, Repare reinforces its commitment to personalized medicine, ensuring that treatment is tailored to the individual genetic profile of patients.
Products
Repare Therapeutics has several key product candidates in its development pipeline aimed at addressing various cancer types:
1. RP-3500:
- Lead Product Candidate: Representing Repare’s flagship program, RP-3500 is under development to exploit a synthetic lethal interaction between the MGMT gene and ATR (Ataxia Telangiectasia and Rad3-related protein).
- Current Development Stage: Primarily in Phase 1 clinical trials, RP-3500 is being evaluated for efficacy in treating solid tumors, including cancers of the ovarian, lung, and colon, which are characterized by specific genetic alterations that may make them susceptible to this treatment.
2. RP-6306:
- Targeting POLQ and PARP Interaction: This product candidate aims at a synthetic lethal relationship between the POLQ (DNA polymerase theta) and PARP (Poly (ADP-ribose) polymerase). This interaction is particularly relevant in various malignancies where mutations confer a vulnerability to therapeutic intervention.
- Development Status: Currently positioned in preclinical development, Repare has plans to transition RP-6306 into clinical trials shortly, indicating a strong pipeline progression.
3. Companion Diagnostics:
- Early Stage Development: The company is also investing efforts in the development of companion diagnostics aimed at recognizing genetic markers that are indicative of tumor responses to their drug candidates. These tools are intended to be integrated with treatment regimens to enhance therapeutic success rates.
Services
In addition to its product offerings, Repare Therapeutics provides a suite of services that support drug discovery and development processes:
1. SNIPRx Platform:
- Innovative Drug Discovery Approach: The SNIPRx platform employs CRISPR technology to identify and validate synthetic lethal targets efficiently. This innovative approach positions Repare at the forefront of identifying novel therapeutic targets that can lead to more effective treatment options.
2. Preclinical and Clinical Development Services:
- Comprehensive Support: Repare possesses significant expertise in both preclinical and clinical development. The company is well-equipped to collaborate with partners by providing services spanning the entirety of drug development phases, from initial target identification through rigorous clinical trial processes.
3. Biomarker Discovery:
- Customized Biomarker Solutions: Repare is involved in biomarker development aimed at profiling caseloads to improve therapeutic outcomes. The company offers services that include the identification and validation of biomarkers, as well as the creation of tailored biomarker panels that align with specific cancer types, facilitating a more precise approach to oncology treatment.
Conclusion
Repare Therapeutics Inc. stands out in the biotechnology landscape with its focus on synthetic lethality, advancing both drug candidates and companion diagnostics to significantly improve cancer treatment outcomes. By harnessing innovative technological platforms and personalized approaches, Repare is positioned to make a substantial impact on the future of oncology therapies.